Medical industry

In 2000, the pharmaceutical industry (English description: Medical Industry) completed a total output value of 233.2 billion yuan, an average annual growth of 17.5%, which is higher than the 15% target of the Ninth Five-Year Plan. The industrial added value reached 57.8 billion yuan, with an average annual growth rate of 15.5%. The total commercial sales of pharmaceuticals was 150.9 billion yuan, an increase of 70.5 billion yuan over 1995, with an average annual growth rate of 13.4%. The total import and export of pharmaceutical products reached US $ 6.4 billion, of which US $ 3.8 billion was exported, an increase of US $ 800 million over 1995, with an average annual growth rate of 4.8%. An outward-oriented pharmaceutical economy was gradually formed. The pharmaceutical industry realized a total of 27 billion yuan in profits and taxes, an increase of 15.5 billion yuan over 1995, an average annual growth rate of 18.6%, and realized profits of 14.38 billion yuan, an increase of 9.43 billion yuan over 1995, an average annual increase of 24.5%. "The plan sets an 18% target. The pharmaceutical business realized a profit of 760 million yuan, an increase of 400 million yuan over 1995 and an average annual growth rate of 16.1%. The pharmaceutical industry realized a situation in which the benefit growth was faster than the total growth, and the mode of economic growth began to change. In 2009, the sales of the third terminal reached 101.4 billion yuan, a year-on-year increase of 26.7%. The year-on-year growth rate of the total revenue and profit of the pharmaceutical industry in August 2010 was 25.69% and 34.71%.

Structural improvement 2. The economic structure of medicine has improved. In the fierce market competition, the pharmaceutical industry through various forms of mergers, mergers and reorganizations, to a certain extent, has changed the situation of small-scale and over-dispersed pharmaceutical companies, and increased production concentration. In the pharmaceutical industry, 25 companies have entered the ranks of 520 large enterprises in the country. The production concentration of the top 60 companies in the pharmaceutical industry sales was 35.7%, which was 16 percentage points higher than the 19.7% at the end of the Eighth Five-Year Plan period. A group of advantageous brand-name companies gradually developed in the fierce market competition. The number of manufacturers of large tonnage products such as penicillin, vitamin C, synthetic vitamin E, aspirin, and paracetamol has been significantly reduced. The production concentration of the first 50 companies in the five categories of tablets, powder injections, water injections, infusions, and capsules reached 44.3%, 97.6%, 66.5%, 58.9%, and 56.2%. The structure of ownership has been further adjusted, and a pattern of common development with multiple ownerships as the mainstay has been basically formed. In terms of output value, the share of the share-holding economy in the entire industry has increased from 12% at the beginning of the Ninth Five-Year Plan period to 33.2%, the "foreign-investment" economy has increased from 15% to 18.8%, and the state-owned economy has fallen from 55% to 36.1%.